Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $21.14.

Several equities analysts have recently commented on the company. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Canaccord Genuity Group reissued a “buy” rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Truist Financial began coverage on Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Morgan Stanley reduced their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th.

Y-mAbs Therapeutics Stock Up 0.5 %

NASDAQ:YMAB opened at $13.21 on Wednesday. The stock’s 50 day moving average price is $12.94 and its two-hundred day moving average price is $13.27. The firm has a market capitalization of $579.69 million, a price-to-earnings ratio of -26.96 and a beta of 0.70. Y-mAbs Therapeutics has a 12-month low of $4.69 and a 12-month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. During the same period in the previous year, the company posted ($0.14) EPS. Equities research analysts expect that Y-mAbs Therapeutics will post -0.57 EPS for the current year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares in the company, valued at $877,822.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Joris Wilms sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock worth $1,338,100 over the last three months. Insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the last quarter. Millennium Management LLC raised its position in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Squarepoint Ops LLC raised its position in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares during the last quarter. Bank of New York Mellon Corp raised its position in Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after purchasing an additional 8,974 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its position in Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after purchasing an additional 3,589 shares during the last quarter. 70.85% of the stock is currently owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.